Using KomPas+ in the Treatment of Patients With Intermittent Claudication
Intermittent Claudication, Peripheral Arterial Disease
About this trial
This is an interventional treatment trial for Intermittent Claudication
Eligibility Criteria
Inclusion Criteria Primary objective:
- All therapists affiliated with Chronisch Zorgnet and specialized in the treatment of people with intermittent claudication are eligible to participate. Besides, all patients referred to a Chronisch Zorgnet therapist with intermittent claudication specialty are eligible to participate.
Inclusion Criteria Secondary objective:
- Provides written informed consent (both therapist and patients)
- Therapists should have finished two KomPas (control group) or KomPas+ (experimental group) e-learnings
- Therapists should have applied KomPas (control group) or KomPas+ (experimental group) to at least one patient with intermittent claudication
Inclusion Criteria Third objective:
- All therapists affiliated with Chronisch Zorgnet and specialized in the treatment of people with intermittent claudication who are included in the experimental group are eligible to participate.
Exclusion Criteria:
- Not applicable due to the "real world" setting of the study.
Sites / Locations
- IQ healthcare, RadboudumcRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Experimental
Control group: no access to KomPas+
Experimental group: access to KomPas+
Therapists in the control group will not have access to KomPas+ and will continue to deliver usual care by using the KNGF guideline. They will also maintain access to KomPas. As with KomPas+, therapists are free to choose whether to use KomPas or not. The use of KomPas will also be encouraged.
KomPas+ will be implemented within the experimental group. The use of KomPas+ in the physiotherapeutic treatment of patients with intermittent claudication will not be mandatory but will be encouraged through an implementation strategy. Therapists are free to choose whether to use it or not.